EMPLOYMENT AGREEMENTEmployment Agreement • May 12th, 2016 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledMay 12th, 2016 Company Industry JurisdictionThis Employment Agreement (the “Agreement”) is made as of May 11, 2016 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Dinah Sah (the “Executive”). Except with respect to the Executive’s Confidentiality, Noncompetition and Assignment Agreement with the Company (the “Employee Agreement”) between the Company and the Executive, the Company’s 2014 Stock Option and Grant Plan and any applicable stock option and/or restricted stock agreements with the Company with respect to equity grants held by the Executive (collectively, the “Equity Documents,”) this Agreement supersedes, amends and restates in all respects all prior agreements and understandings between the Executive and the Company regarding the subject matter herein, including without limitation the March 14, 2014 offer letter provided to the Executive by the Company (the “Prior Offer Letter”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 12th, 2016 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledMay 12th, 2016 Company Industry JurisdictionThis Employment Agreement (the “Agreement”) is made as of May 11, 2016 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Steven M. Paul, MD (the “Executive”). Except with respect to the Executive’s Confidentiality, Noncompetition and Assignment Agreement with the Company (the “Employee Agreement”) between the Company and the Executive, the Company’s 2014 Stock Option and Grant Plan and any applicable stock option and/or restricted stock agreements with the Company with respect to equity grants held by the Executive (collectively, the “Equity Documents,”) this Agreement supersedes, amends and restates in all respects all prior agreements and understandings between the Executive and the Company regarding the subject matter herein, including without limitation the July 24, 2014 offer letter provided to the Executive by the Company (the “Prior Offer Letter”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 12th, 2016 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledMay 12th, 2016 Company Industry JurisdictionThis Employment Agreement (the “Agreement”) is made as of May 11, 2016 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and James Goater (the “Executive”). Except with respect to the Executive’s Confidentiality, Noncompetition and Assignment Agreement with the Company (the “Employee Agreement”) between the Company and the Executive, the Company’s 2014 Stock Option and Grant Plan and any applicable stock option and/or restricted stock agreements with the Company with respect to equity grants held by the Executive (collectively, the “Equity Documents,”) this Agreement supersedes, amends and restates in all respects all prior agreements and understandings between the Executive and the Company regarding the subject matter herein, including without limitation the November 14, 2013 offer letter provided to the Executive by the Company (the “Prior Offer Letter”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 12th, 2016 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledMay 12th, 2016 Company Industry JurisdictionThis Employment Agreement (the “Agreement”) is made as of May 11, 2016 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Robert G Pietrusko (the “Executive”). Except with respect to the Executive’s Confidentiality, Noncompetition and Assignment Agreement with the Company (the “Employee Agreement”) between the Company and the Executive, the Company’s 2014 Stock Option and Grant Plan and any applicable stock option and/or restricted stock agreements with the Company with respect to equity grants held by the Executive (collectively, the “Equity Documents,”) this Agreement supersedes, amends and restates in all respects all prior agreements and understandings between the Executive and the Company regarding the subject matter herein, including without limitation the May 13, 2014 offer letter provided to the Executive by the Company (the “Prior Offer Letter”).